Minerva Neurosciences (NERV) Stock
Early stage biotech developing treatments for brain disorders. Here's the price, business snapshot, and what's worth knowing about Minerva Neurosciences in October 2026.
Minerva Neurosciences, Inc. (NERV) is a clinical‑stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders such as depression, schizophrenia and sleep disturbances. With a small market capitalisation, the company currently has no broad commercial revenue and depends on the progress of its drug candidates, clinical trial outcomes and potential partnerships or licensing deals. That profile makes the shares sensitive to binary events — trial readouts, regulatory decisions and financing news — and therefore more volatile than established pharmaceutical firms. Investors should be aware of liquidity constraints and the risk of dilution if the company raises additional capital. This summary provides general, educational information only and is not personalised investment advice; prospective investors should consider their risk tolerance and consult an authorised financial adviser. Past performance is no guarantee of future returns and the value of any investment can fall as well as rise.
Minerva Neurosciences (NERV) Stock Forecast
Analyst price target, next 12 months
$8.00
+143.9% vs today's $3.28
Price range over the last 12 months
Close to its 12-month low
Analysts covering Minerva Neurosciences have a consensus 12-month target of $8.00, above the current price of $3.28.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Minerva Neurosciences stock with a target price of $8, indicating growth potential.
Financial Health
Minerva Neurosciences is generating strong cash flow per share, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
CNS‑focused pipeline
The company targets central nervous system conditions, so investors often focus on clinical progress and scientific rationale — though trial outcomes can be uncertain.
Clinical readouts ahead
Upcoming trial results and regulatory steps can materially affect valuation. Positive data may lift sentiment, while negative outcomes can be swift and severe.
Small‑cap dynamics
With a modest market capitalisation, the stock may experience high volatility and low liquidity; financing needs could also lead to dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
